Antigenic peptide chain group for treating tumor and application thereof in medicine
A technology of antigenic peptides and drugs, applied in the field of malignant tumor bioimmune drugs, can solve problems such as hearing loss, side effects, blurred vision, etc., and achieve the effect of low incidence of side effects, killing tumor cells, and obvious changes
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0027] Patient A, female, 66 years old, lung adenocarcinoma, liver metastases, clinical stage IV, progression after 6 cycles of vinorelbine monotherapy chemotherapy, targeted drug resistance, lung lesion biopsy, whole exome sequencing and After the HLA typing chip detection, the patient carried the 19DEL mutation, and the HLA typing was HLA-A: A*2103A*3201; HLA-B: B*3217B*3102; HLA-C: C*0302C*0512; HLA-DQB1: DQB1*0201DQB1*1221; HLA-DRB1: DRB1*0201DRB1*0601.
[0028] Use the specific tumor antigen peptide chain SEQ ID No: 1 of the present invention for treatment once a week for a total of 12 weeks. Detect the secretion of specific CD8+Tetramer+T cells by spot detection before and after the injection of the antigen peptide chain group (hereinafter referred to as "medication"), and observe the changes in tumor size 12 weeks before and after the administration by imaging. The results are as follows: figure 1 and figure 2 shown.
[0029] figure 1 HLA*A3101-HVKITDFGR Tetramer s...
Embodiment 2
[0033] Patient B, female, 62 years old, lung adenocarcinoma, pleural metastases, no indication for surgery, treated with gemcitabine + carboplatin intravenous chemotherapy for 6 weeks, progressed after 2 cycles of docetaxel chemotherapy, and progressed after local interventional therapy. After whole exome sequencing and HLA typing chip detection, the patient carried a 19DEL mutation, and the HLA typing was HLA-A: A*0303A*6501; HLA-B: B*0301B*3201; HLA-C: C*0201C *0501; HLA-DQB1: DQB1*0202DQB1*0130; HLA-DRB1: DRB1*0312DRB1*1222.
[0034] Combination therapy with the antigenic peptide chain SEQ ID No: 2 for treating tumors of the present invention, once a week, for 12 weeks in total.
[0035] The changes in the size of lung tumors before and after treatment are as follows: image 3 shown by image 3 It can be seen that before drug treatment, the size of the tumor in the lower lobe of the left lung was 4cm×6cm ( image 3 -A); After 12 weeks of drug treatment, the tumor in the ...
Embodiment 3-100
[0037] Example 3-100 Cancer patients of different types and degrees were taken. After whole exome sequencing and HLA typing chip detection, the patients were all patients with 19DEL mutation, and they were treated with combinations of different antigen peptide chain groups. , once a week for 12 weeks. The results of HLA*A3101-HVKITDFGR Tetramer staining in Example 3-100 and the changes in the size of lung tumors before and after treatment are similar to those in Example 1-2, and will not be repeated here due to space limitations. The above results can all show that the antigen peptide chain group of the present invention can induce dendritic cells that produce tumors, and dendritic cells as antigen-presenting cells can present antigen information to T cells, interact with T cells, and cause T cells to produce tumors. It specifically kills tumor cells, plays a role in killing tumor cells, and the effect is obvious.
[0038] During the treatment of Examples 1-100, ELISA was use...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com